Therapeutic effects of a 12‐week course of alefacept on nail psoriasis

Körver, J.E.M.; Langewouters, A.M.G.; Kerkhof, P.C.M. van de; Pasch, Marcel C.

doi:10.1111/j.1468-3083.2006.01783.x

Cited by 34 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Lamerson et al [13] presented four subjects achieving clearance of their nail psoriasis under efalizumab (Raptiva®) therapy. On the contrary, other reports showed varying response of nail psoriasis treated with alefacept (Amevive®), although both studies had clear limitations [14,15]. …”

Section: Discussionmentioning

confidence: 84%

Marked Improvement in Nail Psoriasis during Treatment with Adalimumab

Irla

Yawalkar

2009

Dermatology

View full text Add to dashboard Cite

Background: Nail involvement is known as a common finding in psoriatic patients and represents a significant impact on patients’ quality of life. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options. Biologicals effective in the treatment of moderate to severe chronic plaque psoriasis may represent a new therapeutic modality for this disease. Adalimumab is a fully human IgG1 monoclonal antibody that binds to tumor necrosis factor α with high affinity and specificity. Observations: We report two cases of rapid improvement in nail psoriasis under adalimumab monotherapy with maintained effectiveness despite intermittent treatment as well as long remission after therapy discontinuation. Conclusion: The marked improvement of our two cases indicates that adalimumab may also help ameliorate nail psoriasis and warrants further controlled studies to establish the effectiveness and therapeutic regimes.

show abstract

Section: Discussionmentioning

confidence: 84%

Marked Improvement in Nail Psoriasis during Treatment with Adalimumab

Irla

Yawalkar

2009

Dermatology

View full text Add to dashboard Cite

show abstract

“…In the second study, eight patients were enrolled for treatment. 18 Baseline severity of nail psoriasis was mild in three patients and moderate to very severe in five patients. At Week 12, three patients (two with moderate to severe nail psoriasis and one with mild nail psoriasis) showed at least 25% improvement in NAPSI score.…”

Section: Alefaceptmentioning

confidence: 99%

Psoriatic Nail Disease: Quality of Life and Treatment

Gupta

Cooper

2009

J Cutan Med Surg

View full text Add to dashboard Cite

Nail psoriasis is common among patients with plaque psoriasis or psoriatic arthritis and has a detrimental effect on quality of life. However, there are currently no standardized therapeutic regimens for nail psoriasis. Traditional treatments for nail psoriasis, which include topical, intralesional, and oral therapies, may be time-consuming, painful, or unsafe when administered long term. Biologic therapies have demonstrated efficacy for plaque psoriasis and psoriatic arthritis; these therapies may be particularly promising for the treatment of nail psoriasis as both groups of patients have an elevated incidence of nail dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically important nail psoriasis improvements using the Nail Psoriasis Severity Index, a helpful tool that, upon validation, will allow comparison across treatments and trials. Large-scale, long-term trials using standardized outcome measures are needed to further evaluate biologic therapies for the treatment of nail psoriasis.

show abstract

“…Additional small clinical studies have been completed with alefacept that support a poor to moderate response in nail psoriasis with demonstrated equivocal results for nail symptoms [43,44,45]. …”

Section: The Advent Of New Treatment Options With Biologic Therapymentioning

confidence: 99%

Treatment and Management of Psoriasis with Nail Involvement: A Focus on Biologic Therapy

Langley

Daudén

2010

Dermatology

View full text Add to dashboard Cite

Nail involvement in psoriasis is typically overlooked, although it can affect up to 50% of patients with psoriasis and cause functional impact as well as psychological stress that can significantly affect quality of life. In addition, psoriatic patients with nail disease tend to have a more severe skin condition, a higher rate of unremitting and progressive arthritis and more associated anxiety and depression. Historically, the treatment of nail psoriasis has proven difficult, with most patients feeling that the treatment for their nail disease was unsatisfactory. The current management of nail psoriasis includes topical, intralesional and systemic therapies, although little clinical evidence is available on the effectiveness of conventional treatments and, consequently, no specific treatment approach has been fully supported. Biologic agents are beginning to emerge as a viable option to treat patients with both cutaneous and nail clinical manifestations of psoriasis and psoriatic arthritis. The extra disease burden that nail symptoms place on the patient can be considered indicative of a more severe form of the disease and should be taken into consideration when assessing treatment options.

show abstract

Therapeutic effects of a 12‐week course of alefacept on nail psoriasis

Cited by 34 publications

References 19 publications

Marked Improvement in Nail Psoriasis during Treatment with Adalimumab

Marked Improvement in Nail Psoriasis during Treatment with Adalimumab

Psoriatic Nail Disease: Quality of Life and Treatment

Treatment and Management of Psoriasis with Nail Involvement: A Focus on Biologic Therapy

Contact Info

Product

Resources

About